[Skip to Content]

RVO

NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal

Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual

Clinical Guidelines

RCOphth Clinical Guidelines The aim of College Clinical Guidelines is to identify the best medical evidence, set standards of patient care and ensure patient safety, providing a benchmark for outcomes within which high quality Ophthalmology can be practiced in the UK health service. Our guidelines are systematically generated to help clinicians make better decisions about appropriate healthcare

Intravitreal Ranibizumab injection for treatment of MO secondary to RVO

College Statement The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 0.5mg ranibizumab intravitreal injection as an option for the treatment of macular oedema secondary to central retinal vein occlusion (CRVO) and selected cases of branch retinal vein occlusion (BRVO) when laser has either